Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors
| Autor: | Fanny Mathias, Cyril Fersing |
|---|---|
| Přispěvatelé: | UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie Radicalaire (ICR), Aix Marseille Université (AMU)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM) |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
business.industry glasdegib PF-04449913 PF-913 acute myeloid leukemia Hedgehog pathway smoothened pf-913 Pharmaceutical Science Myeloid leukemia General Medicine pf-04449913 Hedgehog signaling pathway hedgehog pathway [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication Cancer research Medicine HD9665-9675 business Smoothened Pharmaceutical industry |
| Zdroj: | Acta Pharmaceutica, Vol 72, Iss 1, Pp 9-34 (2022) Acta Pharmaceutica Acta Pharmaceutica, 2021, 72 (1), pp.9-34. ⟨10.2478/acph-2022-0007⟩ Volume 72 Issue 1 |
| ISSN: | 1846-9558 1330-0075 |
| DOI: | 10.2478/acph-2022-0007⟩ |
| Popis: | Numerous new emerging therapies, including oral targeted chemotherapies, have recently entered the therapeutic arsenal against acute myeloid leukemia (AML). The significant shift toward the use of these novel therapeutics, administered either alone or in combination with intensive or low-intensity chemotherapy, changes the prospects for the control of this disease, especially for elderly patients. Glasdegib, an oral Hedgehog pathway inhibitor, showed satisfactory response rates associated with moderate toxicity and less early mortality than standard induction regimens in this population. It was approved in November 2018 by the FDA and in June 2020 by the EMA for use in combination with low-dose cytarabine as a treatment of newly-diagnosed AML in patients aged ≥ 75 and/or unfit for intensive induction chemotherapy. The current paper proposes an extensive, up-to-date review of the preclinical and clinical development of glasdegib. Elements of its routine clinical use and the landscape of ongoing clinical trials are also stated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|